Literature DB >> 27984375

Survival After Pelvic Exenteration for Cervical Cancer: A National Cancer Database Study.

Stephen Graves1, Brandon-Luke L Seagle, Anna E Strohl, Shohreh Shahabi, Wilberto Nieves-Neira.   

Abstract

OBJECTIVE: To determine overall survival (OS) and factors associated with OS after pelvic exenteration for cervical cancer.
METHODS: Women with cervical cancer who underwent exenteration (n = 517) were identified from the 1998 to 2011 National Cancer Database. Kaplan-Meier and multivariate Cox proportional-hazards survival analyses were performed to test for associations of potential explanatory variables with OS. Analyzed confounders included age, insurance status, income, distance from home to treatment center, stage, exenteration type, surgical margin status, and treatment with adjuvant radiation and/or chemotherapy.
RESULTS: Among the entire cohort with clinical follow-up (n = 313), median OS was 24 months. Stage (P = 2.5 × 10), lymph node status (P = 1.3 × 10), insurance status (P = 1.5 × 10), and histologic type (P = 0.04) were significantly associated with OS by the log-rank test. Unadjusted median OS was 24.2 and 61.8 months for women with squamous and adenocarcinoma histologies, respectively. By multivariate Cox regression, age, insurance status, stage, margin status, and adjuvant radiation were associated with OS. Histology was not independently associated with OS on multivariate regression. Among women with node-negative disease, median OS was 73.2 months.
CONCLUSIONS: Exenteration may be curative for more than half of women with node-negative cervical cancer. Stage, insurance status, lymph node status, and surgical margin are independently associated with differential OS after exenteration.

Entities:  

Mesh:

Year:  2017        PMID: 27984375     DOI: 10.1097/IGC.0000000000000884

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Gynecologic Oncology: Pelvic Exenteration for Advanced or Recurring Cervical Cancer - A Single Center Analysis.

Authors:  Luisa Ter Glane; Axel Hegele; Uwe Wagner; Jelena Boekhoff
Journal:  Cancer Diagn Progn       Date:  2022-05-03

2.  Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score.

Authors:  Veronika Seebacher; Alina Sturdza; Birgit Bergmeister; Stephan Polterauer; Christoph Grimm; Alexander Reinthaller; Ziad Hilal; Stefanie Aust
Journal:  Arch Gynecol Obstet       Date:  2018-12-10       Impact factor: 2.344

3.  Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study.

Authors:  Wenxing Yan; Shuang Qiu; Yaming Ding; Qi Zhang; Lihui Si; Sha Lv; Linlin Liu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

4.  Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma.

Authors:  Tao Song; Hong'en Xu; Lei Shi; Senxiang Yan
Journal:  Int J Womens Health       Date:  2022-03-06

5.  The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.

Authors:  Veronika Seebacher; Andrea Rockall; Marielle Nobbenhuis; S Aslam Sohaib; Thomas Knogler; Rosa M Alvarez; Desiree Kolomainen; John H Shepherd; Clare Shaw; Desmond P Barton
Journal:  Arch Gynecol Obstet       Date:  2021-11-03       Impact factor: 2.344

6.  Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer.

Authors:  Agnieszka Lewandowska; Sebastian Szubert; Krzysztof Koper; Agnieszka Koper; Grzegorz Cwynar; Lukasz Wicherek
Journal:  World J Surg Oncol       Date:  2020-09-02       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.